Quanterix has entered a licence agreement with Johnson & Johnson (J&J) company Janssen Sciences Ireland UC (Janssen) to advance the detection of blood-based Alzheimer’s disease.
Under the deal, Quanterix will gain global, non-exclusive rights to the p-Tau 217 antibodies and assay designs of J&J for potential utilisation in clinical research and diagnostic products.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The company will also receive a non-exclusive licence from Janssen for J&J-developed technology for producing Simoa p-Tau 217 research-use-only assay kits to distribute globally.
Quanterix will also introduce a laboratory-developed test based on the J&J p-Tau 217 antibodies and assay. It will be offered via Accelerator under the Lucent Diagnostics brand.
These advancements enable Quanterix to pave the way for the first widely accessible immunoassay-based p-Tau 217 test for clinicians and researchers.
Quanterix CEO Masoud Toloue said: “This collaboration demonstrates the scientific advances that are possible when Simoa’s ultra-sensitive detection is combined with clinically validated antibodies and critical reagents.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“Providing access to high-performing blood-based p-Tau 217 assays are an important step as we work with several partners to build the global infrastructure for non-invasive testing of Alzheimer’s disease.”
Blood-based biomarker tests with high sensitivity and specificity have the potential to enhance early Alzheimer’s disease diagnosis, increasing treatment accessibility for millions of individuals.
Currently, Alzheimer’s diagnosis depends on positron emission tomography or cerebrospinal fluid biomarkers obtained through lumbar puncture.
